PMID- 22613445
OWN - NLM
STAT- MEDLINE
DCOM- 20121113
LR  - 20221207
IS  - 1473-2300 (Electronic)
IS  - 0300-0605 (Linking)
VI  - 40
IP  - 2
DP  - 2012
TI  - Ezetimibe reduces urinary albumin excretion in hypercholesterolaemic type 2 
      diabetes patients with microalbuminuria.
PG  - 798-803
AB  - OBJECTIVE: This study investigated the effects of ezetimibe, an inhibitor of 
      intestinal cholesterol absorption, on early phase diabetic nephropathy. METHODS: 
      A total of 32 hypercholesterolaemic type 2 diabetes patients with 
      microalbuminuria, defined as a urinary albumin excretion (UAE) 30 but < 300 mg/g 
      creatinine, were enrolled. Various clinical and laboratory parameters were 
      determined at baseline and after 6 months of treatment with 10 mg/day ezetimibe. 
      RESULTS: Ezetimibe treatment significantly decreased glycated haemoglobin 
      (HbA(1c)), low-density lipoprotein-cholesterol (LDL-C), triglycerides and UAE, 
      and significantly increased high-density lipoprotein-cholesterol and albumin. It 
      also decreased the serum level of monocyte chemoattractant protein-1 (MCP-1), but 
      this difference was not statistically significant. Univariate analyses showed a 
      correlation between UAE and body mass index, systolic and diastolic blood 
      pressures, HbA(1c), LDL-C, estimated glomerular filtration rate (inverse), 
      creatinine and MCP-1. Since these parameters may be closely correlated with each 
      other, multiple stepwise regression analysis was performed and demonstrated that 
      HbA(1c) and MCP-1 were independent determinants of UAE. CONCLUSIONS: Ezetimibe 
      may be a promising therapeutic strategy for improving albumin excretion, partly 
      through its anti-inflammatory properties, and for reducing LDL-C in 
      hypercholesterolaemic type 2 diabetes patients with microalbuminuria.
FAU - Nakamura, T
AU  - Nakamura T
AD  - Division of Nephrology, Department of Internal Medicine, Shinmatsudo Central 
      General Hospital, Chiba, Japan.
FAU - Sato, E
AU  - Sato E
FAU - Amaha, M
AU  - Amaha M
FAU - Kawagoe, Y
AU  - Kawagoe Y
FAU - Maeda, S
AU  - Maeda S
FAU - Inoue, H
AU  - Inoue H
FAU - Yamagishi, S I
AU  - Yamagishi SI
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - J Int Med Res
JT  - The Journal of international medical research
JID - 0346411
RN  - 0 (Albumins)
RN  - 0 (Azetidines)
RN  - 0 (CCL2 protein, human)
RN  - 0 (Chemokine CCL2)
RN  - 0 (Cholesterol, LDL)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Triglycerides)
RN  - EOR26LQQ24 (Ezetimibe)
SB  - IM
MH  - Albumins/analysis
MH  - Albuminuria/*drug therapy
MH  - Azetidines/pharmacology/*therapeutic use
MH  - Blood Pressure
MH  - Body Mass Index
MH  - Chemokine CCL2/blood
MH  - Cholesterol, LDL/*blood
MH  - Diabetes Mellitus, Type 2/complications/drug therapy
MH  - Diabetic Nephropathies/complications/drug therapy
MH  - Ezetimibe
MH  - Female
MH  - Glycated Hemoglobin/analysis
MH  - Humans
MH  - Hypercholesterolemia/complications/*drug therapy
MH  - Male
MH  - Middle Aged
MH  - Triglycerides/blood
EDAT- 2012/05/23 06:00
MHDA- 2012/11/14 06:00
CRDT- 2012/05/23 06:00
PHST- 2012/05/23 06:00 [entrez]
PHST- 2012/05/23 06:00 [pubmed]
PHST- 2012/11/14 06:00 [medline]
AID - 10.1177/147323001204000246 [doi]
PST - ppublish
SO  - J Int Med Res. 2012;40(2):798-803. doi: 10.1177/147323001204000246.